Hematological Malignancies

Abstract B-cell chronic lymphocytic leukemia (CLL) has been traditionally described as a disease characterized by an accumulation of quiescent small lymphocytes with decreased susceptibility to apoptotic cell death. However, small numbers of "atypical" lymphocytes and prolymphocytes (PL) are frequently observed in the bone marrow (BM) of patients with CLL. In this study, we examined BM biopsy and aspirate specimens obtained from seven patients with atypical CLL. Using a double labeling (Ki-67 + /CD20 + ) immunohistochemical method, we found that an appreciable number of the atypical CLL cells expressed the proliferation-associated protein Ki-67. Because CLL is characterized by a slow change in the peripheral blood (PB) lymphocyte count, we reasoned that a subpopulation of CLL cells probably undergoes spontaneous apoptosis. Using Western blot analysis, we observed expression of procaspase-9, procaspase-10, and poly(ADP-ribose) polymerase by the neoplastic cells in all seven cases of CLL, and procaspase-3 and procaspase-8 expression in six neoplasms. We also detected cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase in four and five CLL cases, respectively. To determine whether CLL cells undergo spontaneous apoptosis, we performed the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay using BM biopsy specimens. We found TUNEL-positive lymphocytes in areas infiltrated by CLL. In summary, our data show that subpopulations of B-lymphocytes are proliferating or undergoing spontaneous apoptotic cell death in patients with atypical CLL.

[1]  C. Geisler,et al.  Nuclear clefts in chronic lymphocytic leukaemia. A light microscopic and ultrastructural study of a new prognostic parameter. , 2009, Scandinavian journal of haematology.

[2]  Marcos González,et al.  Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. , 2003, Blood.

[3]  G. Rassidakis,et al.  Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22). , 2003, American journal of clinical pathology.

[4]  J. O'fallon,et al.  Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia , 2003, British journal of haematology.

[5]  C. Peschel,et al.  Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. , 2003, Experimental hematology.

[6]  Arthur Weiss,et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.

[7]  J. Choi.  Apoptotic rate varies with detection methods in myelodysplastic syndromes: impact of method selection , 2002, European journal of haematology.

[8]  C. Miething,et al.  Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27 , 2002, Leukemia.

[9]  K. Metze,et al.  Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. , 2001, Cytometry.

[10]  Ash A. Alizadeh,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[11]  M Chilosi,et al.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[12]  L. Medeiros,et al.  Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. , 2001, American journal of clinical pathology.

[13]  Z. Estrov,et al.  The Clinical Significance of Caspase Regulation in Acute Leukemia , 2001, Leukemia & lymphoma.

[14]  D. P. Bentley,et al.  The apoptotic pathway: a target for therapy in chronic lymphocytic leukemia , 2000, Hematological oncology.

[15]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[16]  E. Matutes,et al.  Morphological and immunophenotypic features of chronic lymphocytic leukemia. , 2000, Reviews in clinical and experimental hematology.

[17]  P. Thall,et al.  Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[19]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[20]  F. Ajchenbaum‐Cymbalista,et al.  Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder , 1999, Leukemia.

[21]  M. Hallek,et al.  Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival , 1999, Journal of Molecular Medicine.

[22]  D. Catovsky,et al.  Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12 , 1997, British journal of haematology.

[23]  D. Catovsky,et al.  Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia. , 1996, Leukemia.

[24]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[25]  N. Chiorazzi,et al.  Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. , 1996, Blood.

[26]  F. Ajchenbaum‐Cymbalista,et al.  Overexpression of cyclin D2 in chronic B-cell malignancies. , 1995, Blood.

[27]  D. Catovsky,et al.  Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity. , 1992, Leukemia.

[28]  S. Pileri,et al.  Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki‐67 and anti‐bromo‐deoxyuridine monoclonal antibodies , 1988, British journal of haematology.

[29]  K. Lennert,et al.  Growth fractions in malignant non‐Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki‐67 , 1984, Hematological oncology.

[30]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[31]  C. Peschel,et al.  Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. , 2003, Blood.

[32]  Lisa L. Smith,et al.  Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. , 2003, Cancer research.

[33]  J. Byrd,et al.  Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. , 2002, Seminars in oncology.

[34]  K. Kuliczkowski,et al.  Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Haematologica.

[35]  P. Thall,et al.  Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. , 1998, Blood.

[36]  J. Jurlander.  The cellular biology of B-cell chronic lymphocytic leukemia. , 1998, Critical reviews in oncology/hematology.

[37]  R. Gascoyne,et al.  Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. , 1997, Blood.

[38]  G. Flandrin,et al.  Chronic lymphocytic leukaemia with binucleated lymphocytes. , 1997, Leukemia & lymphoma.